Navigation Links
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
Date:5/5/2009

SAN DIEGO, May 5, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report first quarter 2009 financial results after the NASDAQ Global Market closes on Monday, May 11, 2009. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results for the first quarter 2009 and to provide a business and financial update.

The conference call may be accessed by dialing 877.857.6151 for domestic callers and 719.325.4806 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals First Quarter 2009 Earnings Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's ability to obtain additional funds, the timing, success and cost of Arena's lorcaserin program and other of its research and development programs, the risk that results of clinical trials or preclinical studies may not be predictive of future results, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, Arena's ability to partner lorcaserin or other of its compounds or programs, the timing and ability of Arena to receive regulatory approval for its drug candidates, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Contacts:  Jack Lief
    President and Chief Executive Officer

    Cindy McGee
    Senior Communications Associate

    Arena Pharmaceuticals, Inc.
    858.453.7200, ext. 1479

    Mary Claire Duch
    WeissComm Partners
    Media Relations
    212.301.7228


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
2. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
3. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
4. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
5. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
6. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
9. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
10. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
11. ThreeWire Expands Presence in the Pharmaceutical Arena
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... Testing (PROMPT), a research registry built on the secure online PatientCrossroads platform, has ... More than 1,600 participants have joined the PROMPT study, which seeks to advance ...
(Date:2/9/2016)... ... February 09, 2016 , ... With a presidential election in November and the ... will bring together over 500 top healthcare leaders for a night and day of ... organized by MBA students of the University of Pennsylvania’s Wharton School, will be held ...
(Date:2/9/2016)... Prussia, PA (PRWEB) , ... February 09, 2016 , ... ... Development, Europe. Based in Paris, he will focus on acquiring new accounts and ... being met. , “Fred brings to our European clients more than ...
(Date:2/9/2016)... -- This market research report on the global microbiology ... the market in terms of revenue (USD Million). The ... manufacture of microbiology culture media and related products. The ... providing the overall information of various market segments included ... provides the overall information and data analysis of the ...
Breaking Biology Technology:
(Date:2/9/2016)... , Feb. 9, 2016 Vigilant Solutions announces today ... reader (LPR) to develop a lead in a difficult homicide ... LPR data to locate the suspect vehicle. Due to the ... case have been omitted at the agency,s request. ... agency explains, "Our victim was found deceased at an intersection ...
(Date:2/4/2016)... The field of Human Microbiome research ... popular hubs of the biotechnology industry. While the ... of human microbiota, have garnered a lot of ... space has literally exploded in terms of both ... focuses on biomedical aspects of research, development, and ...
(Date:2/3/2016)... 2016 Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases ... from Vigilant Solutions. Brian Wenberg explains, ... victim was walking out of a convenience store and witnessed an elderly male ... vehicle, striking his vehicle and leaving the scene.  In ...
Breaking Biology News(10 mins):